Multiple sclerosis (MS) is a complex, heterogeneous, chronic disease that requires individualized treatment throughout a patient’s life. The disease involves the central nervous system and disrupts the flow of information within the brain and between the brain and body, signaling unpredictable symptoms.1
Over the past four decades, Biogen has been committed to translating science to meaningful advances for the MS community. Our industry-leading portfolio — backed by established safety and efficacy profiles, ongoing investment in our products, as well as our comprehensive services and solutions — enables us to offer a broad range of options to meet the ever-evolving needs of MS patients and drive greater individualized disease management.
As MS disease management and patient needs evolve, Biogen remains focused on novel research initiatives and technological innovations to further the understanding of MS and improve patient outcomes. While we focus on advancing current assets in our pipeline, we aspire to pioneer disruptive therapies for MS prevention and cure through exploration in emerging science, including novel treatment approaches such as vaccine cell-based therapies, exploring new mechanisms of remyelination and neuroprotection, and developing additional preclinical models that have enhanced translational predictability.
Imagine spending years feeling isolated and alone as you navigate a long winding road to diagnosis, searching for answers. You finally hear the words “multiple sclerosis” (MS) and although shocking, you feel some sense of relief to have an answer. But as you search for stories of others who have walked this same path, the faces staring back at you are nothing like your own. Once again, you feel isolated and alone, this time with the shame of feeling different.
A conversation between Dr. Mitzi Joi Williams, an MS expert and practicing neurologist based in Atlanta, GA, and Matt Winton, Ph.D., Senior Vice President and head of U.S. MS Franchise at Biogen, on health inequities that many MS patients experience regarding access to care, discrimination, bias in medicine, and clinical trial representation.
Voted the No. 1 preferred app for people living with MS, the AbyTM and CleoTM Patients Companion App provides resources for people living with MS, such as news and information, a journal to track symptoms, exercise programs, and a nurse chat feature, with the goal of being a valuable addition to their support system.2
As pioneers in neuroscience, Biogen has an innovative therapeutic pipeline that aims to reverse disability, repair damage, and address other remaining unmet needs in MS, with the goal of significantly altering the course of MS and preventing disease development and disability progression. Biogen has active and ongoing MS clinical trials for both investigational and existing therapies. Learn more about our clinical trial recruitment and access.
As a patient of a Biogen treatment or therapy, you have the option of being connected to a Biogen support coordinator who can help answer any questions you may have about treatment and provide one-on-one phone support. Biogen Support Services is also here to provide help with financial assistance, navigating insurance, or learning more about your therapy. Find out about these patient support services.
Above MS is a place where you can connect with the MS community. We hope to create a community where people can share their insights and expertise and learn from others who know what it’s like to live with MS. We are here to help throughout the MS journey, offering relevant disease education, healthy lifestyle information, and everyday inspiration.
For more details, visit AboveMS.com.
An estimated 2.8 million people live with MS worldwide.3
More than 1.8 million people have been treated with a Biogen disease-modifying therapy.
For more than 25 years, we have led in the research and development of new therapies to treat MS.